dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
== Career == White began his academic career as an assistant professor in what is now the department of physiology and biophysics at the University of California, Irvine in 1972. He was promoted to associate professor in 1975, and to professor in 1979. He became professor emeritus in 2012. During his tenure at UCI, he also held concurrent appointments at Brookhaven National Laboratories as guest associate physiologist till 1983, and as guest biophysicist till 1996. He also served as a guest scientist at NIST Center for Neutron Research since 2001. White was appointed vice-chair in the department of physiology and biophysics at UCI from 1974 till 1975, and as chair from 1977 till 1989. In this role, he hired several other faculty, and helped launch their careers.
Validation and Quality Control: It is important to ensure the accuracy and reliability of the integration process, by performing validation and quality control checks to the software itself. This may involve comparing integration results with known standards, replicating analyses, and assessing precision and accuracy Applications are also available for simulation of chromatography, for example for teaching, demonstration, or for method development &/or optimization.
=== Scientific tracking === Freeze branding is one of the few means of permanently distinguishing an animal that meets all of William Ricker's requirements for an effective marking system for wild animal research. Ricker developed his requirements while working as a fisheries scientist. He sought ways to mark animals used in scientific experiments such that their markings did not influence scientific data. His four requirements for such markings are:
Sources: en.wikipedia.org
In May 2026, Buc-ee's sued a small North Georgia-based convenience store chain called Teddy's Market for trademark infringement, alleging that its use of a cartoon bear mascot and a name that uses "two-syllable, six-letter possessives ending in an 'eez' sound" would cause customer confusion. Teddy's filed a counterclaim in August, arguing that the stark differences between two companies, such as the sizes of their stores, the marketing used between them, and Teddy's use of BP-branded fuel pumps instead of in-brand pumps, does not constitute infringement, and that Buc-ee's trademark registrations were improperly obtained. During the episode of Last Week Tonight aired on July 26, 2026, John Oliver launched a merch store entitled "Buc-Off." On this site, he launched various made-to-order products featuring a logo parodying the Buc-ee's logo, with the name "Buc-Off" and the beaver replaced with a squirrel character named Mr. Nutterbutter last seen in a segment about frivolous lawsuits. Oliver launched this site in the hopes that Buc-ee's would sue, and fight back in the hopes of avoiding further lawsuits brought on by Buc-ee's towards smaller companies. All proceeds from the merch sales are being donated to Hunger Free America. In July 2026, Buc-ee's sued a small convenience store chain based in Beavercreek, Ohio called Beaver's Mini Mart, alleging that its beaver logo too closely resembled Buc-ee's own "Bucky" beaver mascot.
college sports) SOD (i/a) School Of Dentistry Statement Of Difference(s) Statement Of Direction Statement Of Documentation Statement Of Duty/Duties SOE (i) Secret Of Evermore Special Operations Executive (WWII British organization) State Of Emissions (EW) SOF (a/i) Special Operations Force(s) Status of Forces SOFIA – (a) Stratospheric Observatory For Infrared Astronomy SOGAT (a) Society of Graphical and Allied Trades Former British printing union SOHC – (i) Single-OverHead-Cam engine SOHO – (p) Solar and Heliospheric Observatory SOI (i) Signal Operating Instruction (i) Southern Oscillation Index SOL – (i) Shit Out of Luck SOLIS – (i) Synoptic Optical Long-term Investigations of the Sun som – (s) Somali language (ISO 639-2 code) SOM (a) Simulation Object Model (s) Somalia (ISO 3166 trigram) Sonar – (p) SOund Navigation And Ranging SOP (i) Standing/Standard Operating Procedure State of Play SOR (i) State Of Readiness Statement Of Requirements SOS (s) Somali shilling (ISO 4217 currency code) Save Our Souls SOSTAR – (a) Stand-Off Surveillance and Target Acquisition Radar sot – (s) Sotho language (ISO 639-2 code) SOUTHAG – (p) Southern Army Group SOUTHCOM – (p) (U.S.) Southern Command SOV – (i) Single Occupant Vehicle SOW – (i) Statement Of Work SOWHAT – (p) RESNA Subcommittee on Wheelchairs and Transportation SOX – (p) Sarbanes–Oxley Act
No metal-adapted endemic taxa have been documented so far. There is, however, evidence for community shifts associated with heavy metals, with lower diversity associated with contaminated sites. On the other hand, soils naturally rich in heavy metals, such as serpentine soils, do not seem to affect the diversity of ectomycorrhizal fungal communities.
==== Infrastructure ==== The conflict resulted in widespread destruction in Lebanon that was particularly seen in the south, east, and Dahieh—the southern suburbs of the capital, Beirut. According to the World Bank, 99,209 houses were damaged during the conflict, of which 18% were destroyed. By 31 October 2024, nearly 25% of the buildings in towns near the border were damaged or destroyed, with the most destruction occurring in Kfar Kila and Ayta ash-Shaab. Roughly 80% of the damage occurred after 2 October. In the areas that the IDF had captured during its ground invasion into Lebanon, 42% of buildings were destroyed, according to NBC News. Amnesty International reported the damaging or destruction of over 10,000 buildings between October 2024 and January 2025, with 70% of the buildings in Yaroun, Dhayra, and Al-Bustan being severely damaged or destroyed. UN-Habitat reported that 27% of buildings in Marjayoun and 15% of buildings in Bint Jbeil were damaged or destroyed, while the mayor of Kfar Kila stated that 90% of the homes in the village were destroyed during the conflict, with the remaining 10% sustaining damage. The scale of destruction in Dahieh was comparable to the 2006 Lebanon war, with 353 buildings in the area being destroyed and more than 6,000 houses damaged. The Hezbollah-linked newspaper Al Akhbar reported that the cost of damages in Dahieh was $630 million. More than 60 schools have been destroyed since September 2024, according to Save the Children.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.